Exploration of Significant Reversible Restrictive Spirometry to Bronchodilator Therapy

The aim of this study is to explore the clinical significance of bronchodilator reversibility in patients with restrictive patterns of spirometry. In restrictive disorders, this is less common than in obstructive airway disease, which is characterized by reversibility on bronchodilator medication as evaluated by pulmonary function testing. In our study, 30 individuals with restricted spirometry who significantly responded to bronchodilators were included. Restriction was characterized by reduced FVC and FEV1, normal FEVI/FVC, and an improvement of 12% and 200 ml in FEV1 and FVC following bronchodilator therapy. The body plethysmography measurements of the diffusing lung capacity, spirometry, clinical history, treatment history, X-ray features, and lung volume for each patient were noted. The mean age was 48.60, + 14.06 years, the majority of the patients were male 70 % and 22.23, + 3 .59 was females BMI which was slightly higher than males .40% were smokers, with shortness of breath as the most common symptom, followed by cough, wheeze and chest pain. Asthma was the most commonly diagnosed medical condition and most of them were on bronchodilators. The mean post-bronchodilator FEV1% and FVC% were 66.88, + 24.28 and 70.95, + 24.99, with a reversibility of 12.91%. The FEV1/FVC% was 96.80, +16.95. The mean TLC was normal whereas the RV, TLC, and RV/TLC were increased. It might have determined that reduced elastic recoil, which results in early airway closure, air trapping, and low lung volumes, may be the source of post-bronchodilator reversibility in patients with restrictive spirometry. Although there are not many of these individuals, if they are symptomatic, bronchodilator treatment might be beneficial.